Ryvu Therapeutics SA (RVU) Stock Statistics & Valuation Metrics

Ryvu Therapeutics SA has a market cap or net worth of zł597.66M. The enterprise value is zł584.93M.

Ryvu Therapeutics SA has 23,120,148 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ryvu Therapeutics SA’s return on equity (ROE) is -0.77 and return on invested capital (ROIC) is -44.95%.

The current PE Ratio of Ryvu Therapeutics SA is ―. Ryvu Therapeutics SA’s PEG ratio is -0.40.

In the last 12 months, Ryvu Therapeutics SA had revenue of 77.97M and earned -111.44M in profits. Earnings per share was -4.82.

In the last 12 months, operating cash flow was -113.94M and capital expenditures -2.42M, giving a free cash flow of -116.36M billion.

Ryvu Therapeutics SA pays an annual dividend of ―, resulting in a dividend yield of ―

Ryvu Therapeutics SA upcoming earnings date is Mar 17, 2026, TBA (Confirmed).

Ryvu Therapeutics SA as a current ratio of 2.52, with Debt / Equity ratio of 99.04%

In the past 12 months, Ryvu Therapeutics SA has paid 297.00K in taxes.

Ryvu Therapeutics SA EV to EBITDA ratio is -8.32, with an EV/FCF ratio of -5.95.

Ryvu Therapeutics SA has zł130.69M in cash and marketable securities with zł70.54M in debt, giving a net cash position of zł60.15M billion.

Gross margin is 19.17%, with operating margin of -156.60%, and net profit margin of -142.92%.

The average price target for Ryvu Therapeutics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―